[Federal Register Volume 78, Number 188 (Friday, September 27, 2013)]
[Notices]
[Pages 59700-59701]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-23534]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-13-0852]


Agency Forms Undergoing Paperwork Reduction Act Review

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
(404) 639-7570 or send an email to [email protected]. Send written comments 
to CDC Desk Officer, Office of Management and Budget, Washington, DC 
20503 or by fax to (202) 395-5806. Written comments should be received 
within 30 days of this notice.

Proposed Project

    Prevalence Survey of Healthcare-Associated Infections (HAIs) and 
Antimicrobial Use in U.S. Acute Care Hospitals--Reinstatement--(0920-
0852 exp 5/31/13)--National Center for Emerging and Zoonotic Infectious 
Diseases, Centers for Disease Control and Prevention (CDC).

Background and Brief Description

    Preventing healthcare-associated infections (HAIs) is a CDC 
priority. An essential step in reducing the occurrence of HAIs is to 
estimate accurately the burden of these infections in U.S. hospitals, 
and to describe the types of HAIs and causative organisms. The scope 
and magnitude of HAIs in the United States were last directly estimated 
in the 1970s in which comprehensive data were collected from a sample 
of 338 hospitals; 5% of hospitalized patients acquired an infection not 
present at the time of admission. Because of the substantial resources 
necessary to conduct hospital-wide surveillance in an ongoing manner, 
most of the more than 4,500 hospitals now reporting to the CDC's 
current HAI surveillance system, the National Healthcare Safety Network 
(NHSN 0920-0666 expiration 1/31/15), focus instead on device-associated 
and procedure-associated infections in selected patient locations, and 
do not report data on all types of HAIs occurring hospital-wide. 
Periodic assessments of the magnitude and types of HAIs occurring in 
all patient populations within acute care hospitals are needed to 
inform decisions by local and national policy makers and by hospital 
infection control personnel regarding appropriate targets and 
strategies for HAI prevention.
    During 2008-2009 in the previous project period, CDC developed a 
pilot protocol for HAI point prevalence survey, conducted over a 1-day 
period at each of nine acute care hospitals in one U.S. city. This 
pilot phase was followed in 2010 by a phase 2, limited roll-out HAI and 
antimicrobial use prevalence survey, conducted during July and August 
in 22 hospitals across 10 Emerging Infections Program (EIP) sites (in 
California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New 
Mexico, New York, Oregon, and Tennessee). Experience gained in the 
phase 1 and phase 2 surveys was used to conduct a full-scale, phase 3 
survey in 2011, involving 183 hospitals in the 10 EIP sites. Over 
11,000 patients were surveyed, and analysis of HAI and antimicrobial 
use data is ongoing at this time.
    This reinstatement is sought, to allow a repeat HAI and 
antimicrobial use prevalence survey to be performed in 2014. A repeat 
survey will allow further refinement of survey methodology and 
assessment of changes over time in prevalence, HAI distribution, and 
pathogen distribution. It will also allow for a re-assessment of the 
burden of antimicrobial use, at a time when antimicrobial stewardship 
is an area of active engagement in many acute care hospitals. The 2014 
survey will be performed in a sample of up to 500 acute care hospitals, 
drawn from the acute care hospital populations in each of the 10 EIP 
sites (and including participation from many hospitals that 
participated in prior phases of the survey). Infection prevention 
personnel in participating hospitals and EIP site personnel will 
collect demographic and clinical data from the medical records of a 
sample of eligible patients in their hospitals on a single day in 2014, 
to identify CDC-defined HAIs. The surveys will provide data for CDC to 
make estimates of the prevalence of HAIs across this sample of U.S. 
hospitals as well as the distribution of infection types and causative 
organisms. These data can be used to work toward reducing and 
eliminating healthcare-associated infections--a Department of Health 
and Human Services (DHHS) Healthy People 2020 objective (http://www.healthypeople.gov/2020/topicsobjectives2020/overview.aspx?topicid=17). This survey project also supports the CDC 
Winnable Battle goal of improving national surveillance for healthcare-
associated infections (http://www.cdc.gov/winnablebattles/Goals.html).
    There are no costs to respondents other than their time. The 
estimated annualized burden is 6,325 hours.

----------------------------------------------------------------------------------------------------------------
                                                                                   Number of      Average burden
             Respondents                     Form name            Number of      responses per     per response
                                                                 respondents       respondent       (in hours)
----------------------------------------------------------------------------------------------------------------
Infection Preventionist.............  Healthcare Facility                  500                1            45/60
                                       Assessment (HCA).
Infection Preventionist.............  Patient Information                  500               42            17/60
                                       Form (PIF).
----------------------------------------------------------------------------------------------------------------



[[Page 59701]]

Kimberly S. Lane,
Deputy Director, Office of Scientific Integrity, Office of the 
Associate Director for Science, Office of the Director, Centers for 
Disease Control and Prevention.
[FR Doc. 2013-23534 Filed 9-26-13; 8:45 am]
BILLING CODE 4163-18-P